Market maker backs HeartChain to revolutionize early-stage research funding
Simon Leger is COO and Head of Token Management at HeartChain. A highly skilled mathematician, for most of his career he has been an algorithmic trader on Wall Street, working in major banks and private trading companies. He has built automated trading systems for high frequency latency sensitive trading, so he understands the technology behind the computerized monetary world.
Simon’s trading expertise and natural curiosity meant he entered the cryptocurrency space in its infancy. He initially became involved back in 2012, as he was fascinated with this new way of transmitting and storing value.
As Leger says, “I bought into Bitcoin in the very early days, more out of curiosity than anything else. I then saw the financial opportunities and developed a trading algorithm. I was one of the first large market makers in the industry, so I quit my Wall Street job and moved to Gibraltar to work fulltime in the crypto world.”
He invested in many ICOs when they first started and is now one of the industry’s most respected hands-on cryptocurrency experts, well connected throughout the world. It was when he was working with Jean-Marc Orlando (Vice-Chairman of HeartChain) doing proof of concept work on start-up Coinrealty, that he met the other partners of what was to become HeartChain.
These doctors and investment bankers were looking to launch a new medtech start-up, but wanted an alternate funding model to the traditional VC method of financing. It soon became obvious the platform that Simon and Jean-Marc were developing, would be perfect for the medtech, biotech and fintech industries. So the new team founded HeartChain and started building the world’s first platform designed to revolutionize funding for early-stage innovation products.
HeartChain already has its first innovation product committed for the launch of the platform, while others are being scrutinized by the expert management team. The first product is called “MyoPatch” and it is a unique, minimally invasive method for stem cell delivery, via a gel-based patch platform technology. It has the potential to completely change treatment of heart disease.
“This is a completely new way that organizations and individuals can participate in bringing life-saving innovations to market. Once the platform is operational we will be launching a continuous pipeline of innovations from the medtech, biotech and fintech categories. There is nothing like this in the world today and it can only exist because of the development of blockchain technology, smart contracts and tokenization of cryptocurrencies.” said Leger.
Get more detailed information and download the whitepaper at www.heartchain.com or join the HeartChain Telegram community at https://t.me/heart_chain
